Economic evaluation of HLA-B*1502 screening for preventing carbamazepine- induced Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) is prioritized by stakeholders under ‘Research for development of health benefit package under universal coverage scheme’. The study carried out an evidence to inform the Subcommittee for Developm

This research aimed to develop the population-based preference scores of the EQ-5D-5L (the 5L), Thai version in an effort to compare the measurement properties of the 5L with those of the EQ-5D-3L (the 3L), and to compare the results of an economic evaluation from a 2014 study that used the 5L compared with the 3L. To elicit population-based prefer

The purpose of this study is to compare the cost-utility of each treatment option available today in order to determine the most cost-effective treatment compared with standard treatment in the social perspective. Research methodology is an economic evaluation by using the markov model to compare the cost and utility of treatment options of new pat

An aim of this project is to prioritise Health Technology Assessment (HTA) topics.Topic prioritisation process consists of three key principles namely,1) the entire process and results must be transparent;2) the process as well as the prioritised list should be reflect benefits of the society; and3) the participation from multiple groups of stakeho

Following an assessment1 of the core strategies of HITAP carried out by a team of Thai and UK investigators in 2007-2008, at the request of the Thai Health Promotion Foundation, HITAP has initiated a second evaluation, in 2011, this time bringing together a team of UK, Thai and Korean assessors. These recommendations were the result of data analysi

Although HITAP strictly follows national HTA methodological guidelines, questions over the good governance of research arose from a lack of formal process guidelines. Therefore, HITAP embarked on the development of HTA process guidelines in 2011. International guidelines were reviewed in order to develop a conceptual framework, with the aim of conn

11-303-2555(10)diabetes mellitus type 1,diabetes mellitus type 2,Insulin,Self-monitoring blood glucose

Imatinib, the first tyrosine kinase inhibitor (TKI) has been used widely as a first-line treatment for newly diagnosed CML patients. Approximately 20-30% of CML patients are resistant or intolerant to the drug, and half of these cases are due to a gene mutation in the ABL domain. Recently, second generation TKIs have emerged, such as dasatinib and

The Union of Myanmar is the largest country in mainland South-East Asia with a population of 57.5 million. It has a pluralistic mix of public and private healthcare systems. Although the Ministry of Health (MoH) is the main organisation responsible for healthcare provision, 70-80% of health service expenditure is now absorbed by the households. Thi

17-207-2555Senior Research Scholar Program,Thailand Research Fund,TRF